Sheri Baker, an RRMM patient advocate, discusses how treatment approaches for relapsed multiple myeloma have evolved over time.
Transcript
When I first started — doing triplet and quadruplet therapy wasn’t as prevalent, especially like it is now.
In the beginning, when I first started, a strong treatment plan was just basically — well, one drug plus a steroid. So a doublet was what we called it.
And then with me being on dialysis and poor kidneys, in the beginning, we were much more careful. We couldn’t be too strong.
Now a strong treatment plan is whatever combination of drugs work for your particular myeloma — which and for everybody, it’s different. I mean, I know there’s a standard of care for newly diagnosed patients, but for relapsed patients, because all of our myelomas are different, that’s just different things to different people.
It could be a doublet, a triplet, it could be CAR-T therapy. And it just depends on how willing you are to deal with whatever the side effects may be for all of those different drugs.
Sometimes you have to be hospitalized, maybe only for one or two days, maybe for longer. It just depends. And so that to me is a strong treatment — going in for a CAR-T and having to be in the hospital for perhaps a week or two or three.
